Lumexa Imaging files for US IPO-February 2024-www.financetom.com

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Lumexa Imaging files for US IPO

Nov 17, 2025 1:44 PM

Nov 17 (Reuters) - Medical imaging firm Lumexa has filed

for a U.S. initial public offering, a Securities and Exchange

Commision filing showed on Monday.

Previous page： --Allient Keeps Quarterly Dividend at $0.03 Per Share, Payable April 3 to Shareholders of Record March 20 Next page： Boise Cascade Insider Sold Shares Worth $1,143,301, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Allient Keeps Quarterly Dividend at $0.03 Per Share, Payable April 3 to Shareholders of Record March 20

Mar 5, 2024

05:48 PM EST, 03/05/2024 (MT Newswires) -- Price: 32.5, Change: +2.5, Percent Change: +8.33 ...

Boise Cascade Insider Sold Shares Worth $1,143,301, According to a Recent SEC Filing

Mar 5, 2024

05:50 PM EST, 03/05/2024 (MT Newswires) -- Mack L Hogans, Director, on March 01, 2024, sold 8,463 shares in Boise Cascade ( BCC ) for $1,143,301. Following the Form 4 filing with the SEC, Hogans has control over a total of 3,055 shares of the company, with 3,055 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1328581/000132858124000032/xslF345X03/wk-form4_1709678798.xml ...

Cigna Insider Sold Shares Worth $649,607, According to a Recent SEC Filing

Mar 5, 2024

05:47 PM EST, 03/05/2024 (MT Newswires) -- Michael W Triplett, Special Advisor, on March 01, 2024, sold 1,953 shares in Cigna ( CI ) for $649,607. Following the Form 4 filing with the SEC, Triplett has control over a total of 40,562 shares of the company, with 32,452 shares held directly and 8,110 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1739940/000122520824003705/xslF345X03/doc4.xml ...

Verastem Gets Orphan Drug Designation From US FDA for Avutometinib to Treat Type of Ovarian Cancer

Mar 5, 2024

05:51 PM EST, 03/05/2024 (MT Newswires) -- Verastem ( VSTM ) said Tuesday the US Food and Drug Administration granted orphan drug designation to avutometinib for the treatment of low-grade serous ovarian cancer. The treatment is on track for submission of a rolling new drug application for accelerated approval in H1 and a potential launch in 2025, the company said....